Abstract

BackgroundLeukocyte immunoglobulin-like receptor A3 (LILRA3) is a putatively secreted protein belongs to the leukocyte immunoglobulin-like receptor (LILR) family. Our previous study provided the first evidence that the functional LILRA3 was...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Mechanism of artesunate on bone destruction in experimental rheumatoid arthritis based on transcriptomics and network pharmacology
Feng-Yu Huang ... Xiao-Hui Su
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica | VOL. 48
Feng-Yu Huang, et. al.Feng-Yu Huang ... Xiao-Hui Su
01 Mar 2023
BAFF, involved in B cell activation through the NF-κB pathway, is related to disease activity and bone destruction in rheumatoid arthritis.
Ling-Ling Zhang ... Ying Li
Acta Pharmacologica Sinica | VOL. 42
Ling-Ling Zhang, et. al.Ling-Ling Zhang ... Ying Li
22 Jan 2021
THU0024 Lack of Association Between IL-15 Genetic Variants and Progression of Joint Destruction in Japanese Rheumatoid Arthritis Patients
S Yoshida ... A Taniguchi
Annals of the Rheumatic Diseases | VOL. 72
S Yoshida, et. al.S Yoshida ... A Taniguchi
01 Jun 2013
Dopaminergic pathway: A potential approach to target specific leukocyte subpopulations in chronic inflammatory joint diseasesThe
-
02 Jun 2021
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.